Proline-rich kinase 2 (Pyk2), also known as CAKbeta (cell adhesion kinase beta), is a cytoplasmic tyrosine kinase that is structurally related to focal adhesion kinase. Pyk2 is expressed in different cell types including brain cells, fibroblasts, platelets, and other hemopoietic cells. Pyk2 is rapidly tyrosine phosphorylated in response to diverse extracellular signals acting via different post receptor pathways. We have investigated whether this protein kinase is functionally expressed in normal and neoplastic prostate tissues. In this study, we demonstrate that Pyk2 is expressed only in normal epithelial prostate tissue and in benign prostatic hyperplasia, whereas its expression progressively declines with an increasing grade of malignancy of prostate cancer.
Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression / Stanzione, Rosita; Picascia, Antonietta; Chieffi, Paolo; Imbimbo, Ciro; Palmieri, Alessandro; Mirone, Vincenzo; Staibano, Stefania; Franco, Renato; DE ROSA, Gaetano; Schlessinger, Joseph; Tramontano, Donatella. - In: LABORATORY INVESTIGATION. - ISSN 0023-6837. - STAMPA. - 81:1(2001), pp. 51-59.
Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression.
PICASCIA, ANTONIETTA;IMBIMBO, CIRO;PALMIERI, ALESSANDRO;MIRONE, VINCENZO;STAIBANO, STEFANIA;FRANCO, RENATO;DE ROSA, GAETANO;TRAMONTANO, DONATELLA
2001
Abstract
Proline-rich kinase 2 (Pyk2), also known as CAKbeta (cell adhesion kinase beta), is a cytoplasmic tyrosine kinase that is structurally related to focal adhesion kinase. Pyk2 is expressed in different cell types including brain cells, fibroblasts, platelets, and other hemopoietic cells. Pyk2 is rapidly tyrosine phosphorylated in response to diverse extracellular signals acting via different post receptor pathways. We have investigated whether this protein kinase is functionally expressed in normal and neoplastic prostate tissues. In this study, we demonstrate that Pyk2 is expressed only in normal epithelial prostate tissue and in benign prostatic hyperplasia, whereas its expression progressively declines with an increasing grade of malignancy of prostate cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.